➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Express Scripts
Johnson and Johnson
Medtronic
Moodys

Last Updated: January 23, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Defactinib

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Defactinib?

Defactinib is an investigational drug.

There have been 19 clinical trials for Defactinib. The most recent clinical trial was a Phase 1 trial, which was initiated on April 30th 2020.

The most common disease conditions in clinical trials are Mesothelioma, Ovarian Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Verastem, Inc., Merck Sharp & Dohme Corp., and Washington University School of Medicine.

There are six US patents protecting this investigational drug and forty-seven international patents.

Recent Clinical Trials for Defactinib
TitleSponsorPhase
Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal MelanomaVerastem, Inc.Phase 2
Defactinib (VS-6063) Combined With VS-6766 in Patients With Metastatic Uveal MelanomaThomas Jefferson UniversityPhase 2
A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V or Other KRAS-Mutant Non-Small Cell Lung CancerVerastem, Inc.Phase 2

See all Defactinib clinical trials

Clinical Trial Summary for Defactinib

Top disease conditions for Defactinib
Top clinical trial sponsors for Defactinib

See all Defactinib clinical trials

US Patents for Defactinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Defactinib   Start Trial Methods and compositions for treating abnormal cell growth Verastem, Inc. (Needham, MA)   Start Trial
Defactinib   Start Trial Sulfonyl amide derivatives for the treatment of abnormal cell growth Pfizer, Inc. (New York, NY)   Start Trial
Defactinib   Start Trial Sulfonyl amide derivatives for the treatment of abnormal cell growth Pfizer Inc (New York, NY)   Start Trial
Defactinib   Start Trial Sulfonyl amide derivatives for the treatment of abnormal cell growth Pfizer Inc (New York, NY)   Start Trial
Defactinib   Start Trial Sulfonyl amide derivatives for the treatment of abnormal cell growth   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Defactinib

Drugname Country Document Number Estimated Expiration Related US Patent
Defactinib Denmark DK3102232 2034-02-07   Start Trial
Defactinib European Patent Office EP3102232 2034-02-07   Start Trial
Defactinib European Patent Office EP3698790 2034-02-07   Start Trial
Defactinib Spain ES2779975 2034-02-07   Start Trial
Defactinib Hong Kong HK1232152 2034-02-07   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Express Scripts
Johnson and Johnson
Medtronic
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.